GE HealthCare Raises 2026 Organic Revenue Guidance to 4% on 12% Backlog Growth

What happened

GE HealthCare raised its full-year 2026 organic revenue growth guidance to 4%, signaling improved confidence in demand. The equipment backlog grew 12% year over year to $23.7 billion, up from $21.8 billion at the end of Q1 2026, indicating a reacceleration in order intake. This reverses the earlier slowdown in organic orders growth observed in Q1 2026 and suggests hospitals are increasing capital spending on imaging equipment. However, the company's profitability remains pressured by tariffs and input-cost inflation, which reduced operating margin by 310 basis points in Q1 2026, and management has not yet demonstrated margin stabilization. The revenue guidance raise and backlog growth strengthen the demand-side thesis, but investors should await confirmation that margins are holding before turning more constructive.

Implication

The 12% backlog growth to $23.7 billion provides multi-quarter revenue visibility and supports the bull case for GEHC's imaging franchise. The raised organic revenue guidance to 4% suggests management is confident in converting that backlog into sales despite prior order deceleration. However, the key risk remains margin compression from tariffs and cost inflation, which caused a significant drop in operating margin in Q1 2026 and may offset top-line gains. Investors should monitor upcoming quarterly reports for evidence that pricing actions and cost controls are restoring profitability to the guided 15.4%–15.7% adjusted EBIT margin range. Until margin trajectory is confirmed, the stock's valuation at ~19x earnings leaves little room for error, so a wait-and-see approach remains prudent.

Thesis delta

The thesis shifts from dual concerns over demand slowdown and margin compression to a more singular focus on margin execution, as backlog expansion reduces revenue risk. The raised revenue guidance suggests management sees improving demand, but profitability remains uncertain due to tariffs and cost inflation. Thus, the overall WAIT stance is maintained but with a slightly more positive tilt if margins can show stabilization.